Antitachycardia devices: Realities and promises  by Klein, Lawrence S. et al.
Antitachycardia Devices: Realities and Promises 
LAWRENCE S. KLEIN. MD, FACC. WILLIAM M. MILES. MD. FACC, 
DOUGLAS P. ZIPES, MD, FACC 
In*iaMpolis, ,“di”“ll 
lionpharmacologic therapy for ventricular arrhythmias has 
gained wowing attention with the development afthe implantable 
csrdiovcrtcr-dePbrillator. In addition, the repoN al adcerre 
cffcctr al drug thcmpy from ~vcwd studies. including the Cardiac 
Arrhythmia Suppressian Trial (CAST), hare suppartcd the need 
ioor lbeso devices. Tb development of new implantable ccrdio- 
wtcrdrtibriUators that have the capability cl antitach)cardia 
pacing, hradycardtn pacing, cardimcrsion and defibrillation hss 
enban& their clinical utilb. 1 
Management of patients with hemodynamically wnponant 
arrhythmias has become an increasingly complex problem 
for cardiologists because of the ever growing available 
treatments for both supravenrricular and ventricular tachy- 
arrhythmias. Impatdnt therapeutic decisions include not 
only when to treat and how tojudge eficacy of treatment t Il. 
but also how to choose from among the many thenptes 
available. including pharmacologic aScots, catheter ablation. 
arrhythmia surgery and antirachycanlia device implanradon. 
Antiarrhythmic Therapy 
The growth and development of aotitachycardia device, 
have been sccelerated by inefficacy or side etTccts. or both. 
inherent in drug manaamcnt. Pharmacoloeic theraw has 
always been th; mainday of treatment for-both su&cn- 
tricular and ventricular arrhythmias. Although antiarrhyth- 
mic medications continue to bc the primary therapy “red by 
most cardiologists treating arrhythmias. an agent capable of 
preventing arrhythmia inducibdity by programmed stimula- 
tion is found in only IO% to 3% of paucntr with lifc- 
thrcateninp ve”triculara~hythmias. although the percentage 
is somewhat higher for patients with rupm~cntrieulsr ar- 
rhyrhmms. Further. side effects from antiarrhythmic medi- 
cauons may prompt discontinuation of. or poor compliance 
with. therapy by many patients. leadinS to drug inefficacy. 
Many patients. espeoally those with supraventricular ar- 
rhythm&. are young and do not find appealing the prospect 
of taking anuarrhythmic medications for many years. panic- 
ularly during childbearing periods. Other problemc \,!*h 
antmrrhythmx medications include arrhylbmia a&wwti”n, 
as emphaslred by the rcecnt CAST trial I?). Some iwe& 
Saton (3-6) have recommended wider use of amiodarone 
either uith or without guidance from electrophysi”:ogic 
testing. bur the risk of side effects (5% to 7% pulmonary 
toxicity risk alonel (7) and significant rccurrcncc rate of 
ventricular tachycardia (10% to 30% at 2 years) (8) has 
limited the usefulness of this drue. 
Codwrrr ahlu,rion has shown ,“nnsc for both ventricular 
(9) and supravenrrieular (IO.1 I) arrhythmias. Ablation has 
been hghly successful for patients with the Wolff-Parkinson- 
White syndrome and atriovcntricular IAV) node reentry. It 
has also been effective in creating heart block as a therapcu- 
tic approach I” placnts with bxractable atrial arrhythmias or 
alrial flutter-fibrillation in whom pharmacologic therapy has 
been unsuccessful. Catheter ablation for ventricular tachy- 
cardia appears to be most useful in “idiopathic” vcnlricular 
tachycardia 112.13) but some SUCCESS has bee,1 reported 
C 14-16) in more common types of this arrhythmia. 
Swwrrv fir rerwiculor rochycardin has been highly sue- 
cessful and- IS now accepted a; standard therapy for many 
patients. Thic approach is limited by the relatively small 
subset of pa~cnts (10% to 15%) *ho arc appropriate candi- 
dates, the srgmficant operative mortality rate (9% to 15%) 
(17-20) and the surgical and mappmg expertise required by 
the physicians performing the procedure. 
Thus. the npetus for the development of antitachycardia 
devices has been strong even though they are in a sense an 
admission of ailure to find a corlive or suppresswe ther- 
apy. Nonetheless, their efticacy and acceptance by patients 
have been excellent and technologic advances in the field ore 
occurring rapidly. This rewew will focus on the current 
~1~1~s of antitachycardia devices, including those that arc 
currently in the investigational stage of development. 
Antitachycardia Pacing 
Tachycurdia Pwvention 
Overdrive atrial or ventricular pacing to suppress ventric- 
ular arrhythmias has been tried. but the long-term success 
for tachycardia suppression is poor in patients with a normal 
heart rate (21.221. Overdrive pacing has been used success- 
fullv 10 prevent tachvcardian that emeree from sinus bradv- 
car&i or AV block or in patients with the long QT syn- 
drome (23.24). Dual-chamber pacing with a short AV 
interval has prevented some supraventricular arrhythmias, 
~articula:Iv AV node reentrv (251. Althooeh this aooroach 
may be hcipfu!, the hemodynamic problem; assoc&d with 
this technique (and curative therapy now available) make it 
clinically unsppealing 12% 
Ofher poring fe-chniqan IU prevrn, !achycordk, onse, 
hove been fried. For example, premature subthreshold stim- 
ulation doting the effective refractory period (Fig. 1) can 
inhibit the next stimulated complex and terminate some 
tachycardias by prolonging local refrdctoriness (26,27). Sub- 
threshold stimulation has not been clinically useful in pre- 
venting the initiation of tachycardia or in terminating tachy- 
card& reliably (28). High current strength pacing at the site 
of origin of tachycardia prevenled induction of ventricular 
tachycardia in oearly 50% of patients io one study 129). 
Although the mechanism of this observation is unclear. the 
frequent finding of multiple ventricular tachycardia configu- 
rations in ao individual patient and the difficulty in maintain- 
ing an electrode at the site of origin of ventricular tachycar- 
dia in the left ventricle limits the clinical utility of this 
technique. 
Tachycardm “annihilafio~~” with use of critically timed 
and positioned subthreshold or hyperpolarizing stimuli has 
been described, but has found httle clinical use exceot for 
parasystolic rhythms 00). Thus. despite the need for why- 
cardia prevention. clinically important and desirable tech- 
niques to achieve it have been frustratingly inadequate. 
Drrecrion of Tachycardia 
Automatic tachycardii detection algorithms. Early gener- 
ations of antitachvcardia devices were oatient ac!+:ated and 
depended on the r&rate interpretationby the patient on th; 
basis of symptoms that the tachycardia had started. More 
recent generations of devices have had automatic tachycar- 
dia dewtion algorithms. Although reliance on rate as the 
only detection criterion has a high sensitivity, specificity is 
low; therefore, other rhythms, either physiologic (sinus 
tachycardia, for example) or pathologic (atrial fibrillation), 
can trigger device discharge and lead to inappropria!: ther- 
apy. Therefore. other criteria to improve the speciticlty of 
tachycardia recognition have been incorporated into some 
devices but with only mixed EUCCOSS. For example. measur- 
ing differences in timing and sequence between two ventric- 
ular electrodes as a means of differentiating premature 
ventricular complexes from sinus beats showed that 14 of 15 
ventricular ectopic configurations exhibited a >.‘tl ms differ- 
ence in timing compared with sinus beats (31). if the ven- 
tricular tachycardia exhibits ventriculoatrial conduction, a 
single premature (80 to IW ms) atria1 extrastimulus can be 
used to exclude sinus tachycardia by failing to produce a 
significant change in ventricular cycle length (32). Electra 
gram analysis can be used to discriminate antemgrade and 
retmgrade atrial depolarization on the basis of amplitude and 
slew rate differences 133). Analysis of simultaneous atrial 
and ventricular recordings to identify AV dissociation (341 
and recording right ventricular pressure (35) can help differ- 
entiate ventricular tachycardia from Gtos tachycardia. 
Other arrhythmia detection criteria. It is quite clear that 
no detection aleorithm is oerfect and the ideal svstem mav - 
need to employ several algorithms. including iiosensors. 
Still. overlapping features of different tachycardias will 
continue to ccur. necessitating individualization of therapy 
by carefully programming the device for each patient. Other 
arrhythmia detection criteria, such as suddenness of lachy- 
cardia onset. rate stability and maintenance of a high rate, 
have improved tachycardia detection algorithms but have 
not been as useful clinically as it was initially hoped (36). 
Tachycardia Termination 
Mwhanism of termination. Many. perhaps most, tachy- 
arrhythmias that occur clinically are due to reentry. Penc- 
tration into the reentrant circuit by a paced complex depends 
on the presence of excitable tissue between the leading edge 
and “tail” of Ihe electrical wave fmnl propagating in the 
circuit (often referred to as the “excitable gap”). A paced 
impulse can reset the tachycardia circuit when it collides 
with the leading edpe of the deoolarizine wave front but 
propagates ant&og~dely in nonrefractory tissue. It then 
advances the tachycardia circuit (37-40). When this ohe- 
nomenon occurs with continuous pacing, the arrhythmia is 
said to be “entrained” (41). At shorter extrastimulus inter- 
vals, the impulse can collide with the propagating waive front 
both anterogradely and retrogradely and terminate the ar- 
rhythmia. The relative refmctoriness of the tissue within the 
“excitable gap,” as determined by the resetting respome of 
tachycardia to an extrastimulus. is a major determinant of 
the ability of the paced extrastimulus to terminate surtained 
monomorphic ventricular tachycardia (36.39). 
TerminatIonalgorithms. The ability to enter the excitable 
gap of a tachycardia circuit depends on the site and timing of 
stimulation and the number and energy of the extrastimuli 
(42). Many algorithms for arrhythmia termination have been 
investigated. However, an algorithm that IS cffectivs in the 
electrophysiology laboratory may not be effectwz once ihe 
patient is ambulatory. Autonomy discharge m response to 
postural changes may alter conduction times and refractory 
periods for both ventricular and supraventrudar arrhyth- 
mias (43). Pacine modes using oacine bursts or ertrastimuli 
introduced as a percent of-the &sed rachycardra rate 
(adaptive modes) are probably wpenor 10 modes using fixed 
or predetermined coupling intervals (44). Further. in *icu of 
the potential risk ofaccelerating venlricular rachycaidm 10 a 
hemodynamically unstable arrhythm’a m up to 36% of 
patients (45). backup defibrillation is mandatory when at- 
tempting pacing termination of ventricular tachyarrhyth- 
miss. A pacing mode using automatically increaGng num- 
bers of stimuli with adaptive coupling intervals I”umven~I 
antitachycardia mode”) has been shown to be effecove and 
is being incorporated into some investigational ntaachycar- 
dia devices (46.47). This method of pacing i5 nore effective 
than single-. double- or overdrive bunt pacmg and termi- 
nated 92% of induced ventricula; tachycardia episodes com- 
pared witb 56% for overdrive burst pacing in the amc 
patients (47). Such adaptive modes reduce Ihc importance of 
spontaneous variatioss in tachycardis cycle- length or 
changes in tachycardia rate induced by pacing. 
Some newer rechniques lhnr we still bwrstiymionnl m- 
elude delivery ofultm rapid trains ofstimuli with frequencies 
up to 100 Hz to obtain a single ventricuhr capture at the end 
of ventricular refractoriness. However. this approach 
achieves a success rate ofonlv 50% to fK for termmation of 
tachycardia (48). As discussed previously. other inveatigza- 
ton have used subthreshold stimulation (“mhibition”) to 
prevent premature ventricular extrastimuli n dogs 126) and 
humans (27) (Fig. II. This technique has also been used to 
terminate both supraventricular 149) and ventricular (501 
tachycardia. Although promising. subthreshold stimulation 
is limited by the requirement of pacing close to the site of the 
reentrant circuit, which may be difficult to find or may 
involve multiple sites. 
Clinical Eficmy of Antitochycnrdiu Axing 
There are few large studies on ehicacy of anritachycardi~ 
pacing. One report (511 of 53 patients who received an 
antitachycardia pacemaker for supraventr~cular and ventnc- 
ular arrhythmias reviewed a 14.year expenence with there 
devices. Among patients with an antitachycardia pacemaker 
for supnventricular tachycardia who were followed up for a 
mean of 68 month>. 93% had uccessful termination of 
tachycardia by pacing at I year and 78% at 5 years. In zn 
Patients with an antitachvcardia oacemaker for termmatlon 
if ventricular tachycardia followed up for a mean of 37 
months. efhcacy was slated to be 78% at I year nd 55% at 
5 years. The occurrence of wdden death ,n 4 of these ?,I 
patients was not believed to be related to the pacemaker. 
In a multicenter wdy IS?) 63 patwnt~ had an antitachy- 
cardia pacemakel implanted for cupnwentricubu arrhyth. 
mias and were followed up for 30 months. Gf these patients. 
45% had arrhythmra control with pacemaker therapy alone. 
49% requirrd concurrent drug therapy for control of recur- 
rent arrhythmaas. 6% were nonresp&ders and 6%) rcquircd 
expL.mticn of the pulse generator for a variety of reasons. A
third study (531 dcmotwrated an improvement in employ- 
abdit) and quality of life in patients who received an 
automatic antitachycardia pacemaker for supraventricular 
tacbycardia. In the period bf testing noted e&x, lack of 
backup defibrillauon in antitachycardia pacemakers prc- 
cluded their use in patients with.ventric&r ;achyarrh& 
miab. Now that wch backup is available, indications for 
implantin% these devices will expand and larger clinical 
rrudles will clarify the role of antitachycardia pacing in 
pauent\ wi;h ventricular tachycardis. 
Risk of ventricular fibrillation. The most tmportant bmi- 
tauon ofantltachycardia p cing for pauents with ventricular 
tachycardm II the risk that the arrhythmia wdl accelerate to 
ventnculx fibrdlauon. This event occurs m more than one 
third of paGent> when pacing is used during electrophyrio- 
logic studies to terminate ventricular tachycardia (54). Avail- 
abdity of backup defibrillation in the ~amc device eliminates 
sudden cardiac death from this change in rhythm but does 
not preven; ryncope. In patients with m antitachycardia 
nacemdker lo: wnravtmricular tachvarrhvthmias. recomti- 
iion of coexistent arrhythmias not am~nab~c to antitachy& 
die pacing, such as atrial fibrillation. can be a difficull 
problem. 
Induction ol atrial fibrillation or flutter during Paring to 
terminate suoravonlrtcular tsehvcardias. This has been 
noted in up io 8% of trials and. in 30% of patients 155). 
Pacmg-induced atrlal fibrillation was sustainedin 15% of the 
patients in these trials (551, an event that is potentially 
catastrophic in patients with the Wolff-Parkinson-White syn- 
drome. who may be subject to rapid anterograde conduction 
over an accessory pathway (56). 
SlU?w?IUly 
Antitachycardia pacemakers have a limited clinical mle 
as the sole therapy for supraventricular arrhythmias partic- 
ularly because catheter ablation techniques can eliminate 
most of the tachycardias to be treated. Occasionally. in a 
patient who also has symptomatic bradyarrhythmias the.1 
require pacing. antitachycardia pacing for supraventricular 
tachycardia may be indicated. Antitachycardia pacemakers 
without backup defibrillatioa are contraindicated for patients 
with ventricular tachycardia. Devices with combined anti- 
techycardia pacing. biadycardia pacing and defibrillation are 
currently under investigation and are described below. 
Cardioversion and Defibrillation 
Mechanism 
Cardiaversion. Most episodes of sustained ventricular 
tachycardta are probably due to reentry, although this origin 
is difficult to prove definitively. Successful cardioversion 
of ventricular tachycrrdia is thought to be due to depolar- 
ization of tissue (either partially or fully recovered and 
therefore excitable) in the reentrant circuit. Low energy 
shocks ~0.05 .I) were shown by Saksena et al. (57) to 
capture excitable myocardium loc&y and then spread to the 
origin of ventricular tachycardia. Higher energy shacks 
PO.5 1) captured sites in the ventricle both at the sire of 
origin of ventricular tachycardia and at distant snes. Cardio- 
version of ventricular tachycardia, particularly with low 
energy shocks, must be synchronized to the QRS complex to 
avoid activating myocardium during the vulnerable period 
(early to midportion of the T wave on the scalar electrocar- 
d&am IECGI) when recovery of myocardial excitability is 
not uniform and induction of ventricuiar fibrillation or rem- 
ductmn of ventricular tachycardia is more likely (581. 
Defibrillation. The mechanism of defibrillation is proba- 
bly different from that of electrical cardiaversion for ventric- 
ular tachycardia. Zipes et al. (59) showed that a critical mass 
of ventricular myocardium must be depolarized during de- 
fibrillation to terminate ventricular fibrillation. The size of 
this critical mars is often <IOO% of the ventricular myocar- 
dium (60). Others (61) have demonstrated the need to 
achieve a critical threshold energy (in dogs) for successful 
defibrillation. Lower energy levels caused local defibrilla- 
tion. but also reinitiation of ventricular fibrillation in other 
tissues, leading to failure of the shock to terminate ventric- 
ular fibrillation. 
Low Energy Cordioversion 
Several investigators (62-2-66) have demonstrated the fea- 
sibility of low energy synchronous cardioversion of ventric- 
ular tachycardia with use ofa catheter electrode. After these 
initial studies, an implantable catheter cardioverting system 
was implanted in seven highly selected patients with slow. 
hemodynamically tolerated ventricular tachycardii (67). In 
that study all episodes of ventricular tachycardia had to be 
reliably terminated with 51.7 .I on at least three separate 
occasions without evidence of acceleration of the arrhyth- 
mia. One of these seven patients was discharged from the 
hospital with the device in an automatic mode and had 
recurrence of ventricular tachycardia. The cardioverier dis- 
charge temxinated the tachycardia but caused atrial tibrilla- 
tion that led to prompt hospitalization. The new arrhythmia 
led to a ventricular rate response above the rate threshold 
and resulted in several automatically delivered shocks; one 
of these produced ventricular fibrillation from which the 
patient was promptly resuscitated. This study demonstrated 
both the feasibility of low energy cardioversion and the need 
for backup defibrillation. 
As of 1987.31 cardioverten (Medtmnic model 7210) had 
been implanted (68). Because of the limited applicability of 
the device, the concept of the implantable cardioverter wa?. 
subsequently incorporated into devices also capable of 
backup defibrillation. The eflicacy of low etwgy cardiover- 
sion in terminating ventricular tachycardia is equal to that of 
antitachycardia pacing (69.70). However, arrhythmia accel- 
eration rates were higher with cardioversion and shocks 
were less well tolerated than with pacing. Also, low energy 
cardioversion resulted in a 23% incidence of atrial arrhytb- 
miss. a phenomenon not seen with antitachycardia pacing 
(69). 
Implantable Cardioverter-Defibrillators 
Inditions. The North American Society of Pacing and 
Electrophysiology has provided a set ofindicttion~ for 
implantation of a cardioverterldelibrillator (71). Three 
classes of indications have been suggested: class 1. the 
consensus is that implantable cardioverter-defibrillator ther- 
raw is indicated: cbs, II. such theraw is an o&m. but a 
consensus does not exist: and c/as; m. such therapy is 
generally not justified. The following were suggested as class 
I indications: I) one or more episodes of spontaneous 
sustained ventricular tachycardia or ventricular tiiirillation in 
a patient in whom ekctrophysiologic testing or spontaneous 
ventricular arrhythmias. or both, could not be used accu- 
rately to predict efficacy of the therapies. 21 recurrent gram spend? on rhe isocleclric line. Theorerically. rhe prob- 
episodes of rpantaneous sustained ventricular tachycardia abili,y denstty fuunclion should distinguish ventricular fib& 
or ventricular fibrillation despite antiarrhythmic drug ther- i;,t”n and wdc QRS tachycardias. such as ventricular 
spy (added by electroohvsioloejc testine or noninvasive tachvcardla. ,hd, soend ““Iv a small wnion of the cardiac 
&hods); 3) &ntaneo;s &stained vent&“lar tacbycardm cycle a, the ~~“elc&ic line from n&w QRS supraven,ric- 
or ventricular fibrillation when antiarrhythmic drug therapy ular iachywdtas that occupy the ‘soelearic line for a 
is limited by intolerance or noncompliance: and 41 persislent zreater “r”“““l”” of the cardiac cvctc. In fact. however. ,he 
inducibilityof clinically relevant s&tamed ventricu~artachy- 
cardia or ventricular fibrillation a, elcctrophysiologic study 
&ring administration of the best available drug therapy or 
despite surgical or catheter ablation in a patient with spon- 
taneou~ sustained ventricular tachycardia or ventricular 
fibrillaion. 
&se four class I indicarions for b~rplnnmhlr ca dio- 
vene,.defbr;llotor therapy con be red,rccd 10 dzr fdlowin~~ 
the patient has ventricular tachycardia or ventricular libril- 
lation for which no other therapy is successful by virtue of 
drug inefficacy or patient intolerance or noncompliance: 
sureical or ablation theraov is conuaindicated: OF no satis- 
clinical&y of the probability d;nsity function is marpina, 
and may prevent the appropriate detection of ventncular 
tachycardia with a relatively narrow QRS complex and may 
increase the time required for arrhythmia detection (731. The 
model I550 has a programmable rachycardia detection ra,e 
and the probabday density function can be aclivated o: 
deactivated 
,l’irk 11~s rarr~wrlr osoifoble device. when the rate 
counter has recorded eigh, beats that fulfill the rate-detection 
crtterion. a charging cycle is starled after a delay of 2.5 s to 
uswe that the arrhythmia IS sustained. Including the time 
rewired for arrhvthmia recoenilion (~5 51. a 2.5 s delav and 
fac& end point exists tb;udge therapeutic eficacy. ch&ng tune &lly 6 I”-7 s). the total duration bf an 
Class II indications include syncope of undetermined arrhyrhmia before delivery of a defibrillation shock is usually 
origin it, a patient with clinically relevan, sustained ventric- <!5 s. The debee is “committed.” meaning that once an 
ulartachvcardiaorventricular fibrillation induced at electm- arrhvthmm has been detected and the capacilors have been 
physiolo& study in whom antiarrhythmic drug ,herapy IS 
limited by drug inefficacy or patient intolerance or noncom- 
pliance. 
Clans III indicarions i,wlude I) sustained ventrular 
tachycardia or ventricular fibrillation rha, is me&ted by 
acute &hernia or infarction or of a 10.x:” or metabolic origin 
and amenable to correc,i”n or wverwdi,y: 2) recurrent 
syncope of undetermined origin in a patient without induc- 
ible sustained ventricular tachvarrhvthmia?: 3) incessant 
char&d. a ahock will be delivered whether or no, the 
anhythmta has spomancously terminated. If the arrhyrhmia 
is not terminitted with the first shock. B second detection 
inlerval begins and ,he capaci,ors are recharged. As many as 
five shocks can be delivered for a single arrhythmic even,. 
An interval of at least 35 sofa cardiac rhythm Iha, does not 
satisfy the detecuon crileria llhat is. return of sinus rhythm1 
must elapse before the device resets and is capable of 
deliverine other defibrillation shocks. 
ventricular tachyarrhytbmias; 4) ven,&ular fibrillation sec- Et&. ‘The rate of sudden cardiac dealh after implan- 
ondwy to atrial fibrillation in the Wolff-Parkinson-White muon of the AICD has averaged 27+x 174-77). This rate 
syndrome in a patient whose bypass ,ract is amenable 1” compares favorably with that of hisiorical control patients 
surgical or catheter ablation; and 5) surgical. medIcal or who have survived sudden cardiac death and who have a 
psychiatric contraindications. recurrence rate of 20% to 30% at I to 2 years of follow-up 
S~eefications wd functions. Currenlly only the AICD (78.79). When one combines sudden dealh and “appropri- 
(Cardiac Pacemakers) is approved by the Food and Drug ate” shocks 1” arrive at a “total sudden death incidence.” an 
Administration in the United States, although other devices actuarial survival rate free of sudden cardiac death (sudden 
are currently under investigation and several should be deaths and aborted sudden deaths) of 56% at I yearand 14% 
approved soon. More rhan 7.Cih3 nonprognmmable AlCDs at 4 years for patrenrs with an AlCD has been reponed ,801. 
have been implanted worldwide. The current generation of Overall. among all patients with an implantable defibrillator. 
the device (model ,550) weighs 235 g. displaces 145 cc and is the incidence of at leas, one AICD discharge for a presumed 
powered by two lithium-rilver vanadium pentoxide cells. sustamed vemricular arrhythmia (that is. a” “appropriale” 
The pulse generaor delivers truncated exponential shocks of shock) is 34% (811. It is more difficult to show an impact on 
26 or 30 1 synchronized to the detected QRS complex by a overall survival. One recent multicenter study (82) of 955 
sensing circuit. The device is capable of debvering up to ?Do patents reported a 62.S% survival rate at 6 years of follow- 
shocks over its life span, which averages 24 to 36 months. up, Patien,s ah” develop ventricular tachycardiaor ventnc- 
Bipolarsensinp of rkr ~r,,rrirrrlorrlrr,ro~rrr,n delcrmincr ulsr RbrilMun aim usually have left ventricular dysfunction 
the detected hear, rate and acts ,” synchronize delivery of due to either coronary disease or cardiomyopathy. Thus. 
the cardiovening shock. usually over IWO silicone-insulated although ventricular tachywdia and ventricular fibrillation 
epicardial or per&dial pate+ leads positioned on the righ, may be well managed by the implanlnblc dcfibrillalor, con- 
and left ventricles (72). In addttion. ,he AICD offers the ges,ive hear, failure. recurrent myocardial infarction and 
probability densily funcrion. which i) an analyris of the occasionally pulmonary embolism remain unponan, causes 
proportion of the cardiac cyck that the ventr~~w electro- of dearh in many of these patients. Because of the unan- 
wered questions about overall survival data. several con- 
trolled. randomized studies have been established. compar- 
ing implantation of a cardioverter-defibrillator with other 
furm, of treatmmt. 
Limitations and complications. The perioperauve mortal- 
ity associated with cardior,erter-defibrillator implantation 
has generally been 2% to 3% (X3-871. with the most signifi- 
cam compltcatton being infection. averaging about 5% 
(range 1% to 20%) (83-87). Manifestattons of infection may 
occur as long ns 8.5 months after implantation and uswlly 
require exptanatmn of the entire system (gcncrator and 
leads) for wccelrful treatment. Other complications have 
Included myocardial mfarction. pneumonia. pericardial and 
plewal cffusions. ccrcbrovascular accidents. coronary ar- 
ier: laceration. constrtctive pericarditis and. in earl& se- 
ries. mirration of Ihe superior vena cava electrode (83-88). 
The bnpbnroblc ~nrd~““~~~l~,-d~~ifibrillnlur i+t ia orrenrly 
meilnblr dmg,z has snvml lirnirarimrs b! nddirimt to cow 
plica/iotu oJimp/nnrarior~. The device is large and requires a 
thoracotomy with sobxiphoid or subcostal incision for lead 
implantation. The lack of programmability of the 30 .l output 
requires that wmc patienls receive shocks that have higher 
energy than ncccssaiy (89.90). This higher energy level may 
result in not only patient discomfort, but also early battery 
depletion. Battery life, initially very short in early devices, 
continues to be less than desirable, requiring reopen&m to 
replace rhe generator and increasing :he risk of infection. 
The lack of antitachycardia pacing tn currently available 
defibrillators rcquircs separate antitzhycardia devices or, as 
is more commonly practtced, terminatton of sustained yen- 
tricular tachycardia with a high energy shock. Also. about 
IO% of patients undergoing defibrillator implantation need 
concomitant bradycardia pacing, which at present requires 
implanvation of two devices t82.86.91.92). thereby creating 
the potential for mappropriate device-device interactions. 
Rare progrommbili~? is (I rmw oddirion and its absence 
in earlier models requited occasional generator changes 
simply to change the device rate cut&‘. Current devices are 
committed. causing shocks to be delivered even though the 
arrhythmia may have terminated spontaneously during 
chargmg. In addition, Ihe present generation defibrillator 
requires radiographic cludies and investigation using “beep- 
o-grams’* (93) for suspected sensing problems because the 
device lacks telemetry. Newer devices provide information 
that helps the physician determine the cause for suspected 
spurious shocks (Fig. 21. Cardiac arrest has been docu- 
mented because of fractured defibrillator leads whose integ- 
rity could be checked only by dehvery of a defibrillation 
pulse (861. Spurious device discharges because of failure to 
differentiate supraventricular from ventriculx lachycardia 
have occurred tn IO% to 40% of patients (85.87.94.95). Also. 
lack of telemetry makes determination of the appropriate- 
nebh of a discharge difficult. 
Lnsrly. inuppmprifm inrmmctiom benvern nr~rinvhyrh- 
mic tnedicnrionr and lhc AICD hoe beeu drscribed. Ir. 
earlier defibrillator mode!s, because the rate threshold for 
EGM -- 
, /+f-Y+,p 
Figure 1. Derermination al the cause for suspected spurious device 
discharges m a patient with an implanted Guardian 4201 defibril- 
tator. Manipuladon of the device generator within the pocket 
resulted in oversensing during sinus rhythm. iis shown on the 
marker channel. and accounted for Ihe occwrence of device ds- 
charges during sinus rhythm. When manipulation of the device is 
stopped. the device senses appropriately. Replacement of the gen- 
erator salved the problem. EGM = “enlric”tar ctectrogram. 
tachycardia detection was fixed, drug-induced slowing of 
ventricular tachycardia would occasionally reduce the ien- 
tricular tachycardia rate below the detection rate of the 
defibrillator and necessttae implantation of a new device. 
Pharmacologic therapy has also been shown to have varied 
eRects on energy requirements for successful defibrillation, 
with several agents increasing this requirement (85.86). 
Thus, repeat electrophysiologic testing with arrhythmia in- 
duction and confimmtion of successful defibrillation by the 
device is recommended after any change in antiarrhythmic 
drug therapy. Because the AICD does not have the capabil- 
ity for electrophysiologic testing, such testing requires tram- 
venous catheter placement. 
New Devices 
Although the perfect device is not yet available, several 
implantable cardiovener-defibrillators are currently under- 
going clinical investigation. Many ofihe desirable features of 
the “ideal device” (Table I) are being mcorporated into 
these devices. Future generations will have even more. 
Importunt ferrttrre~ qf t/w newer investigational devices 
ore listed in Table 2. Although none is an ideal device, each 
has distinct advantages over currently available devices. 
Table 2 lists the devices under investigation by each of the 
major manufacturers. A recent review of these devices (96) 
has summarized the advantages and disadvantages of each. 
Although devices capable of antitachycardia pacing with 
backup defibrillation are being developed. some implantable 
cardioverter-detibrillators with additional features other than 
anlitachycardia pacing (such as low energy cardioversion or 
bradycardia pacing. or both) may soon be approved for 
implantation. 
paricnf\ rccetrsd Ihrientak Pm phase 1 and II I& (darn 
“n file. Cardmc Pacemakers). A total of 813 “entricular 
txhvcardm, were Induced at clectrophysiologic study. Six- 
ty-cne 17.55, of the ventricular tachycwdnr were acceler- 
ated aith a low energy 5hock: 56 of these 61 lachycudiar 
had a rate 11801mm. Only five “slow” (<180/min) vemric- 
u!ar tachycardmr were ac&lcratcd with a low energy shock. 
Although the protocol called for 55 I ufenergy delivery. the 
arwunt of energy delivered was nor a factor m dererminmg 
aherher ven,ncular tachycardia ncceler~fion occurred. 
PRX dt~trt~. Phase I trials bf the PRX device (Cardiac 
Pacemakers) have recently been completed. Like the other 
dewce,. lhii implantable cardiovener-defibrillator has the 
capitbility of bradycardia pacmg. antitachycardia pacmg. 
programm:d sumulat~on and defibnllation. At tbc ttmc of 
1% writing. 17 p&n.s have received the device (data on 
file. CPII. The mean partent age was 65 years and 79% of the 
patients had coronary artery disease. The mean ejection 
fractmn wa !35? Monomorphic sustained ventrular 
tachvcardia was mesent in 81% of the oalients. oolvmomhic 
Nine patients have received saonmnco~s shocks and no 
txhyarrhyihmic deaths have been reported. 
Guardian 420.213 and ATP 14210) (Teleclronics). The 
Guardian defibrillator also has low energy synchronous 
cardioversion. but its predominant advantages are: I) hrady- 
cardia pacing. and 2) reconlirmation that ventricular tachy- 
cardia is still present and the ability to “dump” the charge 
imernallv if the arrhvthmia has terminated before deliverv of 
the sh&k (Table iI. Our preliminary report (97) oE 24 
patients with an imolanted Guardian 420213 defibrillator 
ihowed that seven patients had had episodes of diverted 
shacks (that is, the capacitors charged but no shock was 
delivered) for nonauslained ventricu!ar tochvardm. Reoro- 
gr;mming the device decreased the frequency of or eiimi- 
nated these diverted shocks in four paiients and no patient 
had an inappropriate shock. One patient who had received 
frequent spurioos shocks (shocks not for ventricular tachy- 
cardia) from an automatic imolantable cardioverter- 
defibrillator had no spurious shock for 7 months after the 
device was replaced with a Guardian defibrillator. Thus, 
multiprogrammability, telemetrv, permanent ventricular de- 
mand (VW) pacing, tachycardia reconfirmation and a pro- 
grammable detection algorithm offered improvements over 
first generation devices. Figure 3 shows intraopemtive test- 
ing with the Guardian defibrillator device. 
Tlw Teleclronics G~ordiw ATP (model 4210) is also 
currenlly under inws~igotion. This device has bmdycardia 
wing (low and htgh output). antitachycardia pacing. a 
maximal shock energy of 40 J and a minimal shock energy of 
0.5 I. Its shocks arc synchronized and are delivered overtwo 
defibrillator patches. The device is not capable of noninva- 
sive programmed stimulation at this time, hut programmed 
stimulation can be performed using ventricular triggered 
WVT) pacing techmques through the device. It has exten- 
sive telemetry capabilities. 
There are very prsliminots implunr dam on rhe Guardian 
ATP device. In one series (981. five patients received this 
system. Two of the five patients had several spontaneous 
ventricular tachycardia episodes that were terminated suc- 
cessfully by antitachycardia pacing or defibrillation. or spon- 
taneous ventrictdar fibrillation episodes that were success- 
fully defibrillated over a 2 month follow-up period. All five 
patients required bradycardia support. 
PCD (Medtmnic). The Medtronic PCD weighs I97 g in its 
current design (72178). It is a committed device for ventric- 
ular fibrillation but not for veatricular tachycardia. It has 
bradycardia pacing capabilities, is prograt&able and has a 
maximal shock energy of 34 J and a minimal cardioversion 
energy of 0.2 I. Shocks can be delivered over two or three 
patches and bidirectional/sequential shocks may be deliv- 
ered through the device. It cannot deliverhiphasic shocks. A 
nonthoracotomy lead system using either a coronary sinus 
lead or subctttaneous patch in the left thorax may be utilized. 
It can perform noninvasive electrophysiologic testing (Table 
2). 
A report by Yee et al. (991 revealed preliminary results in 
four patients with the PCD 7215. Over a follow-up Period of 
1.5 to 23 months, 161 spotttatteous episodes of ventricular 
tachycardia and 9 episodes meeting the ventricular libtilla- 
lion criterion were detected and treated by the device. Ramp 
pacing terminated 140 ventricular tachycardia episodes and 
WBS successful 88.5% of the time, whereas IO episodes 
(7.2%) required low energy epicardial caniioversion (4 to 
10 I). Six episodes (4.3%) terminated spOmaaeously before 
delivery of therapy. All nine spontaneous episodes of ven- 
tricular fibrillation were delibtillated with shocks of IO to 
I5 J. No complications, malfunction of the device or inap- 
propriate delivery of therapy was observed. 
We have reporred UCUJ our experience wirh the PCD 
Wdrronic 72161 in I2 parients. Shock therapy was admin- 
istered over two epicardial patches in five patients and over 
three patches in six patients (in a sequential or simultaneous 
fashion), or through tra”s~enous leads and a subcutaneous 
patch (one patient). Nine patients had automatic theravy for 
spontaneous arrhythmias: pacing for ventricular tachycardia 
in seven. shocks for ventricular tachycardn in four and 
shocks for ventricular fibrillation in three. Four patients 
were unaware of ventricular tacbycardia onset or termina- 
tion. Failure to detect and terminate ventricular tachvcardta 
that was slower than the detection rate wa, corre;ted by 
reprogramming (two patients). One pvtient bud pacmg- 
induced acceleration of ventricular tachycardia to uentncu- 
lar fibrillation with subsequent detection and automatic 
defibrillation. One wtient with slow ventricuk txhwardra 
(lZO/min) had sin& tacbycardia that trigered ve”&lar 
tachycardia pacing that. in turn, induced ventricular tnchy- 
cardia and subsequent shocks. Neither mechanxcal dertce 
failure “or failure to recognize a tachycardia occurred 
Figure 4 illustrates some of the features of this dewce. 
namely. “oninvasive programmed stimulauo”. antitachycar- 
dia pacing and bradycardia pacing. 
An experience wilh IO pnrims with u! t~~~plnnrcd PCD 
defibrilbror is WIV in pruu f/011. The patient, received 
model 7216A or 72178. All paticnl~ had coronary disease 
and sustained ventricular tnchycardia not wppressed by 
antiarrhgthmic drug rherapy: two patients had a nonthora- 
cotomy lead system. The l”west effecuve defibnlletto” en- 
ergy nnged from j to 18 .I (mea” I?.?) far the epicardial 
electrode cy<tems and was 15 and 18 J for the “onthoracot- 
amy lead m,pla”ts. Follow-up ranged from 7 IO 19 months 
lmeo” 13.8). Spontaneous tachyarrbythmia epicodes were 
detecred and treated by the device in six patients: five of 
them received ‘Waged” (tiered) therapy. No deeths oc- 
curred and no howital admissions were necessary for device 
or ventncular tachyarrhythmia-related complications. 
To ddtc. 347 valie”ts in the U.S. have received the PCD 
defibrillator U,x,&ls 7216Al7217B3 ldata “n Ale. Medtronicl. 
The mea” follow-up time is 6 months. wth a maxImal 
follow-up time of 18.6 months. The mra” patient age was 58 
years. lndtcatlcns foi implantation were vc”~ricular fibrilla- 
don 128%). venlriculer lachycmdia (52%) and ventricular electrogram rate and RR interval stability and configuration. 
taehvcardialfibrillaiion 119%). Sevcntv-four nercrnt of ~a- a definitive cauw for device activation was established in all , 
ticnts had coronary anery diseare: the mean ejection fric- three patients (atrial fibrillation. polymorphic ventricular 
uon was 34%. The mean defibrillation threshold was Y J. tachycardia and rate-sensing lead disruption. respectively). 
Four thousand tacntg-nine episodes of spontaneous ventrtc- Re5.Q (Intermedics). This is a defibrillator that aI50 has 
ular tachycardia have occurred during follow-up and the the capability of antitachycardia pacing and bradycardia 
sscccss rate for automatic termination of ventricular tachv- mxinc. Contoured natches have been develooed to be 
cardia by the device was 97.1%. The actuarial survival r& &npatible with the device. These patches. along with 
Ifor sudden cardiac death) was 91.2%. biphasic shocks. may reduce defibrillation threshold in some 
Cadence (Veetritex). Thts 240 g device has the capability patients. The Res-Q can be used for noninvasive electro- 
of performing antitachycardia pacing. bmdycardia pacing physiologic testing (Table 2). 
and defibrillation with B maximal energy of 34 1. Synchro- A preliminen expwicncc with rhr Rcs-Q was reported by 
nized cardiovereion to 0. I J may be utilized. The shocks are Nntlmn et al. f/M) in rkrre parienrr. All units were im- 
dcbvered over two oatcher. This device can deliver a shock olanted with laree surface area asvmmetrical contoured 
with use of a biph&ic energy waveform. Noninvasive elec- 
truohvsiolwic testinf! can be vetformed with the Cadence 
(TabI; 2) ai ventri&ar elect~ograms can be recorded with 
it and possibly aid m the diagnosis of spontaneous arrhyth- 
mias in patientr with the devise. 
Wink/c cr al. llO2~ hmr described rkeir aperiencr with 
the Cadence in 58 consm~/ive potiem. A total of 350 
epiwdes of ventricular tachyarrhythmia. including 68 epi- 
sodes of sustained ventricular tachycardia and 282 episodes 
of ventricular fibrillation, were induced. Antitachycardia 
pacing was attempted in 45 of the 68 episodes of ventricular 
patches placed e&rdially. Defibriliation thresholds were 
0.6. 5.2. and 3.2 I, respectively. in the three patients. At 
testing after implantation, all devices terminated ventricular 
tachycardia with pacing and ventricular fibrillation with 
defibrillation. At follow-up (IS. 14 and 7 weeks after implan- 
tation, respectively). one device appropriately treated spon- 
taneous ventricular fibrillation and two devices appropri- 
ately paced for ventricular tachycardia. Two of the patients 
were regularly using bradycardia pacing, and all patients 
were receiving antiarrhythmic medications to reduce the 
frequencv of arrhythmias. There were no maim txohkms. 
&hy&wdia. It was successful in 23 episodes, failed in 9 and $iecu& Wemt~slPaeesetter). This is a 2od g defibrillator 
accelerated the tachycardia in 13. In all 22 cases of failure or with antitachycardia and hradycsrdia pacing. It is acommit- 
acceleration the arrhylhmia was terminated by cardioversion ted device in its current design and can deliver a maximal 
or delivery of ventricular fibrillation therapy. An attempt shock of 40 J and a minimal cardioversion energy of 2.5 J. 
was made to convert 23 episodes of ventricular tachycardia The shocks are delivered over two patches. It does not have 
with shocks delivered at an average energy level of 6 J. sequential shock, bidirectional shock or biphasic shock 
Sixteen episodes were successfully terminated by the shock: capabilities. Noninvasive electrophysiologic &sting can be 
during 6 episalcs the arrhythmia stopped during charging performed from the device (Table 2). 
and the shock was not delivered to :he patient. In one At rhe present rime. five pofienrs have received the 
episode venlricular tachycardia was accelerated to ventric- Simm device (SiemenslPacesetter) in England. Of these 
uldr fibrillation that was subsequently successfully termi- five patierds. none has yet had a spontaneous arrhythmia. 
nated by the device. The device terminated a total of 303 Both epicardial and endowdial pacing electmdes have been 
episodes of ventricular fibrillation in 172 casts by the first used. The shock electrodes were all epicardial (data on file, 
shock delivered (average energy level 10 Jj. Forty episodes SiemenslPacesetterl. 
of ventricular fibrillation terminated spontaneously during 
the initial charging and no shock was delivered. The first 
shock failed in 91 instances and a second shock averaging Future Directions 
25 J was required. It was successful in 70 instances and Nonthorscotomy lend systems. Although much work has 
unsuccessful in 6: in the remaining I5 instances. the arrhyth- explored the applicability of transvenous cardioversion and 
mia terminated during second-shock charging and no shock defibrillation !:05-108). more recently B nonthoracotomy 
was delivered. All six arrhythmias in which a second shock svstem usinc one or more transvenous catheters and a chest 
failed were terminaled su&essfully by a third shock at an &II electr& for defibrillation (Fig. 51 has been tested 
energy level averaging 38 I. Thus, all 350 episodes of clinically (109,l IO). Combinations of electrodes in the supe. 
induced arrhythmias either terminated spontaneously or rior vena cwa. coronary sinus and right ventricular apex are 
were successfully terminated by the device. Bradycardia being tested toEether with the chest wall electrode. In 
pacing, noninvasive programmed stimulation and stored general. defibrillation thresholds of 518 I can he achieved in 
diagnostic data functioned without detectable problems. about 75% of pztients using nonthoracotomy lead placement 
A recent report (103) described the value of ventricttlar often employing sequential shocks. I1 would seem likely that 
electrogrdms in the diagnosis of arrhythmias causing electri- impmvements in electrode design and energy waveform will 
cal devices to administer shock therapy. Three patients had increase that figure to 80% to 90% and will make this the 
the Cadence defibrillator system implanted. By analyzing the method of choice for cardioverterldefibrillator implantslion. 
or& lead sysrem. The parienr has s 
Medmnic 7216.4 defibrdlator. Trans- 
venous leads are in the right ventricle 
and right atrium. Sensing is accom- 
plished from the right ventricle. Defibril- 
tation occurs through lwo sequenlial 
pathways u ingthree defibrdlaling leads: 
right “c”,ridc, rupiur vena cava-ngh, 
atria! jwctian and submuscular patch 
Men wr the left homilhwaxl. One of 
these leads serves as a Xx,,,,,on-’ elec- 
trode. 
Energy wave forms. B!d!rectional square wave or wun- 
caled c;gonential shocks provide rucce>\ful de6britMun 
more than monophasic shocks in experimental and clinical 
studies(lll.ll2). Useofa biphasic waveformshou;drequire 
lower energy shocks that will result in potentially ess patient 
discomfort, less battery depletion and possibly a higher 
percentage of acceptable defibrillation thresholds using 
nonthoracotomy lead systems (113). 
Sequential pulse detihrittstiin. Whether sequential pulse 
defibrillation offers any advantage over single pulse defibril- 
lation is controversial. Studies in pigs f I I4 and in humans 
(115) suggest a reduction in defibtiilafion threshold using 
sequential, BE compared with single. shocks. However. 
other studies (I 16) have shown a comparable deiibri ‘ation 
threshold with both techniques. It may be that srqu I 
shocks offer an advantage when defibrillation thresh‘ 
elevated. It does seem inpwtant, however, that the defibrd- 
Mine enemy oas through the intraventricular se~tun~ bc- 
cause all pathways inco&rating the septum have a lower 
defibrillation threshold than those that do not , ,171. 
Conel&om. Major advances have been. and continue to 
be. made in the field of antitachycardia devices. As we 
approach the development of the ideal device that can be 
implanted without thoracotomy. the therapeutic hoices of 
physicians who care for patients with life-lhrearening ven- 
tricular arrhythmias continue to increase. The six devices 
currently under development that are capable of liered 
therapy rep xent a major advance in Ihe management of 
patients with life-threatening ventricular arrhythmia. 
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